Short Interest in Gyre Therapeutics, Inc. (NASDAQ:GYRE) Grows By 51.5%

Gyre Therapeutics, Inc. (NASDAQ:GYRE) was the target of a large growth in short interest in December. As of December 15th, there was short interest totalling 832,200 shares, a growth of 51.5% from the November 30th total of 549,400 shares. Currently, 3.8% of the shares of the company are sold short. Based on an average daily trading volume, of 78,700 shares, the short-interest ratio is presently 10.6 days.

Gyre Therapeutics Trading Down 5.2 %

GYRE stock traded down $0.68 during midday trading on Friday, reaching $12.45. 155,388 shares of the company’s stock traded hands, compared to its average volume of 75,608. The company has a 50-day moving average price of $12.71 and a two-hundred day moving average price of $12.63. Gyre Therapeutics has a 52 week low of $8.26 and a 52 week high of $27.45.

Institutional Trading of Gyre Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in GYRE. FMR LLC bought a new position in Gyre Therapeutics in the 3rd quarter worth about $47,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Gyre Therapeutics by 392.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock worth $1,425,000 after buying an additional 90,557 shares in the last quarter. Rhumbline Advisers bought a new position in shares of Gyre Therapeutics in the second quarter valued at approximately $123,000. Renaissance Technologies LLC purchased a new position in Gyre Therapeutics during the second quarter valued at approximately $166,000. Finally, WINTON GROUP Ltd purchased a new position in Gyre Therapeutics during the second quarter valued at approximately $220,000. 23.99% of the stock is currently owned by institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.